It actually is a broader combination of issues than what you've delineated.
In the early days of the pandemic it was important to really quickly be able to scale up and get vaccines into the arms of Canadians, and that capacity did not reside within Canada to do that, hence the partnering with pharmaceuticals to be able to bring that to the table for Canadians rapidly.
We made a massive investment—at CIHR alone, over $300 million. If you look across all of our agencies, you see there was close to almost $800 million of funding into research for very basic...right from therapies, best interventions, to new nucleotide therapies, and so on. We made the investments really rapidly into the basic research to try to pay the dividends, but we needed to bridge that, and that's where the pharmaceuticals came in.
It was a strong vote of confidence in our academic centres and the ability for them to turn on a dime to produce that.